13D Filing: Birchview Capital and Yield10 Bioscience Inc. (YTEN)

Item 5 of the Schedule 13D
is hereby amended and restated in its entirety as follows:

(a)       The
aggregate percentage of shares of Common Stock reported owned by each person named herein is based upon 8,661,379 shares of Common
Stock outstanding. This latter number of shares of Common Stock is arrived at by adding the number of shares of Common Stock reported
as being outstanding in the Issuer’s 10-K filed December 21, 2017 (8,581,603 shares of Common Stock) to the number of shares
of Common Stock (79,776 shares of Common Stock) which would be receivable by the Reporting Persons if they were to convert all
of the Issuer’s Warrants held by them into shares of Common Stock.

(b)       As
of the date hereof, the Fund beneficially owned 186,079 shares of Common Stock, representing approximately 2.2% of the shares of
the Common Stock of the Issuer outstanding. (The Investment Manager is the investment manager of the Fund and may be deemed to
have sole power to direct the voting and disposition of the shares of Common Stock held by the Fund (the “Fund Shares”).
The Manager is a member of the Fund and may be deemed to have sole power to direct the voting and disposition of the Fund Shares.
The GP is the general partner of the Investment Manager and may be deemed to have sole power to direct the voting and disposition
of the Fund Shares. Mr. Strobeck is the sole member of the GP, a partner of the Investment Manager and sole member and principal
of the Manager and has the power to direct the voting and disposition of the Fund Shares. Each of the Reporting Persons disclaims
beneficial ownership of the Fund Shares except to the extent of their pecuniary interest therein, if any.